LSL Pharma Group Inc. (TSXV:LSL)
Canada · Delayed Price · Currency is CAD 0.3500
-0.0050 (-1.41%)
At close: Aug 10, 2026
LSL Pharma Group Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jul '21 Jul 31, 2021 |
| 34.42 | 28.74 | 17.75 | 10.03 | 8.21 | - | |
Revenue Growth | 70.31% | 61.96% | 76.98% | 22.08% | - | - |
Cost of Revenue | 30.65 | 23.64 | 12.4 | 8.38 | 10.39 | - |
Gross Profit | 3.77 | 5.1 | 5.35 | 1.65 | -2.17 | - |
Selling, General & Admin | 8.16 | 7.23 | 4.52 | 3.64 | 3.92 | - |
Research & Development | - | - | - | - | 0.67 | - |
Other Operating Expenses | 0.18 | 0.18 | 0.42 | 4.67 | 0.43 | 0.06 |
Total Operating Expenses | 8.34 | 7.41 | 4.94 | 8.31 | 5.01 | 0.06 |
Operating Income | -4.4 | -2.13 | 0.82 | -2 | -13.94 | -0.06 |
Interest Expense | -3.4 | -3 | -1.9 | -1.81 | -0.88 | -3.1 |
Other Non-Operating Income (Expense) | 1.67 | 2.43 | 4.86 | - | - | - |
Total Non-Operating Income (Expense) | -1.73 | -0.58 | 2.96 | -1.81 | -0.88 | -3.1 |
Pretax Income | -6.12 | -2.89 | 3.37 | -8.47 | -8.06 | -3.16 |
Provision for Income Taxes | - | -0.07 | 0.05 | - | - | - |
Net Income | -6.12 | -2.82 | 3.32 | -8.47 | -8.06 | -3.16 |
Net Income to Common | -5.48 | -2.82 | 3.32 | -8.47 | -8.06 | 0.09 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 183 | 118 | 105 | 80 | 67 | 21 |
Shares Outstanding (Diluted) | 183 | 118 | 105 | 80 | 67 | 21 |
Shares Change | 112.36% | 11.58% | 31.13% | 19.66% | 225.39% | - |
EPS (Basic) | -0.03 | -0.02 | 0.03 | -0.11 | -0.12 | 0.00 |
EPS (Diluted) | -0.03 | -0.02 | 0.03 | -0.11 | -0.12 | 0.00 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jul '21 Jul 31, 2021 |
Free Cash Flow | -7.39 | -4.46 | -4.77 | -7.73 | -4.16 | 0 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -0.04 | -0.04 | -0.05 | -0.10 | -0.06 | - |
Gross Margin | 10.94% | 17.75% | 30.13% | 16.40% | -26.44% | - |
Operating Margin | -12.77% | -7.41% | 4.64% | -19.93% | -169.70% | - |
Profit Margin | -17.79% | -9.81% | 18.69% | -84.48% | -98.15% | - |
FCF Margin | -21.47% | -15.53% | -26.89% | -77.04% | -50.66% | - |
EBITDA | -1.52 | 0.4 | 2.33 | -0.87 | -12.89 | -0.06 |
EBITDA Margin | -4.42% | 1.40% | 13.15% | -8.68% | -156.95% | - |
EBIT | -4.4 | -2.13 | 0.82 | -2 | -13.94 | -0.06 |
EBIT Margin | -12.77% | -7.41% | 4.64% | -19.93% | -169.70% | - |
Effective Tax Rate | - | 2.25% | 1.49% | 0.00% | 0.00% | 0.00% |